MDxHealth Valuation

Is 0O8G undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0O8G when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0O8G's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0O8G's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0O8G?

Key metric: As 0O8G is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 0O8G. This is calculated by dividing 0O8G's market cap by their current revenue.
What is 0O8G's PS Ratio?
PS Ratio	1x
Sales	US$70.19m
Market Cap	US$70.95m

0O8G key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.3x
Enterprise Value/EBITDA	-4.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 0O8G's PS Ratio compare to its peers?

The above table shows the PS ratio for 0O8G vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	7.4x
AREC Arecor Therapeutics	5.8x	35.2%	UK£28.3m
TRX Tissue Regenix Group	1.6x	15.1%	UK£40.6m
AVCT Avacta Group	7.9x	0.4%	UK£170.1m
BVXP Bioventix	14.4x	n/a	UK£195.7m
0O8G MDxHealth	1x	13.3%	€70.9m

Price-To-Sales vs Peers: 0O8G is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (14.1x).

Price to Sales Ratio vs Industry

How does 0O8G's PS Ratio compare vs other companies in the GB Biotechs Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	7.9x	19.4%
0O8G MDxHealth	1x	13.3%	US$70.95m
GNS Genus	1.7x	3.5%	US$1.41b
OXB Oxford Biomedica	4.5x	21.0%	US$553.81m

7 Companies		Estimated Growth	Market Cap
Industry Avg.	7.9x	37.0%
0O8G MDxHealth	1x	51.6%	US$70.95m

No more companies

Price-To-Sales vs Industry: 0O8G is good value based on its Price-To-Sales Ratio (1x) compared to the UK Biotechs industry average (19.1x).

Price to Sales Ratio vs Fair Ratio

What is 0O8G's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0O8G PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	1x
Fair PS Ratio	3.2x

Price-To-Sales vs Fair Ratio: 0O8G is good value based on its Price-To-Sales Ratio (1x) compared to the estimated Fair Price-To-Sales Ratio (3.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

1.5%

14.6%

hVIVO

UK£149.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

-16.2%

22.2%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$748.39

-1.7%

-6.3%